Cargando…

Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC

BACKGROUND: Pioglitazone, a synthetic peroxisome proliferator activated receptor (PPAR-γ) ligand, is known as an antidiabetic drug included in the thiazolidinediones (TZDs) class. It regulates the lipid and glucose cell metabolism and recently a role in the inhibition of numerous cancer cell process...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciaramella, Vincenza, Sasso, Ferdinando Carlo, Di Liello, Raimondo, Corte, Carminia Maria Della, Barra, Giusi, Viscardi, Giuseppe, Esposito, Giovanna, Sparano, Francesca, Troiani, Teresa, Martinelli, Erika, Orditura, Michele, De Vita, Ferdinando, Ciardiello, Fortunato, Morgillo, Floriana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485164/ https://www.ncbi.nlm.nih.gov/pubmed/31027492 http://dx.doi.org/10.1186/s13046-019-1176-1

Ejemplares similares

Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study
por: Di Liello, Raimondo, et al.
Publicado: (2019)

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells
por: Della Corte, Carminia Maria, et al.
Publicado: (2015)

Role and targeting of anaplastic lymphoma kinase in cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2018)

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
por: Della Corte, Carminia Maria, et al.
Publicado: (2019)

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
por: Morgillo, Floriana, et al.
Publicado: (2017)

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
por: Papaccio, Federica, et al.
Publicado: (2018)

Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
por: Morgillo, Floriana, et al.
Publicado: (2011)

Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives
por: Ciaramella, Vincenza, et al.
Publicado: (2018)

Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer
por: Fasano, Morena, et al.
Publicado: (2020)

Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the COVID-19 Pandemic
por: Napolitano, Stefania, et al.
Publicado: (2022)

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
por: Troiani, Teresa, et al.
Publicado: (2016)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Corte, Carminia Maria Della, et al.
Publicado: (2022)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
por: Festino, Lucia, et al.
Publicado: (2013)

Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer
por: Morgillo, Floriana, et al.
Publicado: (2017)

Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma
por: Di Liello, Raimondo, et al.
Publicado: (2019)

Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial
por: Della Corte, Carminia Maria, et al.
Publicado: (2022)

Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis
por: D’Abrosca, Brigida, et al.
Publicado: (2019)

Implication of the Hedgehog pathway in hepatocellular carcinoma
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’
por: De Falco, Vincenzo, et al.
Publicado: (2020)

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
por: Vitiello, Pietro Paolo, et al.
Publicado: (2019)

Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
por: Caputo, Vincenza, et al.
Publicado: (2022)

Mechanisms of resistance to EGFR-targeted drugs: lung cancer
por: Morgillo, Floriana, et al.
Publicado: (2016)

Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells
por: Ciaramella, Vincenza, et al.
Publicado: (2018)

Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy
por: Fasano, Morena, et al.
Publicado: (2021)

How I treat malignant pleural mesothelioma
por: Viscardi, Giuseppe, et al.
Publicado: (2020)

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells
por: Napolitano, Stefania, et al.
Publicado: (2017)

Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy
por: Fasano, Morena, et al.
Publicado: (2015)

Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2014)

Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota
por: Morgillo, Floriana, et al.
Publicado: (2018)

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care
por: Martinelli, Erika, et al.
Publicado: (2007)

Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype
por: Ciardiello, Davide, et al.
Publicado: (2021)

Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review
por: Fasano, Morena, et al.
Publicado: (2016)

A Trimodality, Four-Step Treatment including Chemotherapy, Pleurectomy/Decortication and Radiotherapy in Early-Stage Malignant Pleural Mesothelioma: A Single-Institution Retrospective Case Series Study
por: Vicidomini, Giovanni, et al.
Publicado: (2021)

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
por: Fasano, Morena, et al.
Publicado: (2022)

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
por: Della Corte, Carminia Maria, et al.
Publicado: (2022)

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets
por: Martini, Giulia, et al.
Publicado: (2017)

Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
por: Caputo, Vincenza, et al.
Publicado: (2023)

AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma
por: Zito Marino, Federica, et al.
Publicado: (2022)

Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_siateki1krah773jj6049mq328